Colinz Labs shareholders approve all resolutions at 40th AGM

scanx
Reviewed by
Anirudha BScanX News Team
Key Highlights
  • All four resolutions at the 40th AGM passed with requisite majority
  • Promoters voted in favour of all leadership reappointments
  • Only 6 votes against recorded across all resolutions
  • No physical attendance; all participation via VC/OAVM
powered bylight_fuzz_icon
51626877

*this image is generated using AI for illustrative purposes only.

Colinz Laboratories Limited shareholders have approved all resolutions proposed at the company's 40th Annual General Meeting, held on September 22, 2026. The voting results, disclosed on September 23, 2026, confirm the adoption of FY26 financial statements and key governance changes.

The meeting was conducted via Video Conferencing or Other Audio Video Means (OAVM). Mrs. Vijaya Mani served as Chairperson. She confirmed the presence of a quorum and acknowledged the sad demise of Late Dr. Mani L.S., the Founder Director and Promoter, during the financial year.

Key resolutions approved

The Board commended several items of business for member approval, covering both ordinary and special business. The audited financial statements for the year ended March 31, 2026, along with the reports of the Board of Directors and Auditors, were adopted.

Resolution Type Details
Adoption of Financial Statements Ordinary For the year ended March 31, 2026
Reappointment of Director Ordinary Mr. N. K. Menon (DIN-01111297) retiring by rotation
Appointment of Director Ordinary Mrs. Vijaya Mani (DIN: 11363910) as Non-Executive Non-Independent Director
Reappointment of CEO Special Mr. N. K. Menon as Whole Time Director & Chief Executive Officer

Governance updates

Mr. N. K. Menon, who serves as the Whole Time Director and Chief Executive Officer, was reappointed following his retirement by rotation. Additionally, members approved his continued remuneration package through a special resolution. Mrs. Vijaya Mani was formally appointed as a Director in her capacity as a Non-Executive Non-Independent Director.

Voting results and attendance

The scrutinizer's report dated September 23, 2026, detailed the voting outcomes. A total of 32 shareholders participated in the voting process, combining remote e-voting and electronic voting during the meeting. Notably, no shareholders attended the meeting in person or through proxy.

Attendance via Video Conferencing included 14 promoters/promoter group members and 18 public shareholders. The total number of shareholders on record was 3,195.

Resolution-wise voting summary

Resolution Votes in Favour Votes Against Result
Adoption of Financial Statements 12,61,269 6 Passed
Reappointment of Director (N.K. Menon) 12,61,169 6 Passed
Appointment of Director (Vijaya Mani) 3,90,769 6 Passed
Reappointment of CEO (N.K. Menon) 12,61,169 6 Passed

The promoters and promoter group held 12,74,659 shares and cast votes on 8,70,500 shares for most resolutions, voting entirely in favour. Public non-institutional shareholders voted on approximately 3,90,675 shares, with only 6 votes cast against across all resolutions.

The meeting concluded at 3:03 pm after the Chairperson informed members that the results of the e-voting would be reconciled by the Scrutinizer, M/s. Ashwini Vaze & Associates. The final report is now available on the company website and relevant stock exchange platforms.

Historical Stock Returns for Colinz Laboratories

1 Day5 Days1 Month6 Months1 Year5 Years
0.0%-4.15%0.0%0.0%0.0%0.0%

How will the formal appointment of Mrs. Vijaya Mani as a Non-Executive Non-Independent Director influence Colinz Laboratories' strategic direction following the passing of founder Dr. Mani L.S.?

What are the implications of the extremely low shareholder participation (less than 1% of registered holders) for the company's future corporate governance credibility and market perception?

Will the reappointment of CEO N.K. Menon with an approved remuneration package signal a continuation of existing operational strategies or indicate a shift in management priorities for FY27?

Colinz Laboratories open offer sees only six shares tendered at ₹54

scanx
Reviewed by
Jubin VScanX News Team
Key Highlights
  • Only six equity shares were tendered in the open offer for Colinz Laboratories, valuing just ₹324 against a potential ₹3.54 crore.
  • Acquirers Annjana Dugar, Likhitta Dugar, and Antariksh Dugar offered ₹54 per share to buy up to 26% of the voting share capital.
  • The open offer was triggered by a pending Share Purchase Agreement for 8,70,500 shares (34.56%) which remains unconsummated.
  • Public shareholding stands at 34.39% post-offer, subject to downward revision upon reclassification of promoter-held shares.
powered bylight_fuzz_icon
50092433

*this image is generated using AI for illustrative purposes only.

The open offer for Colinz Laboratories attracted negligible interest from public shareholders, with only six equity shares tendered during the offer period that ran from August 7 to August 20, 2026.

Acquirers Annjana Dugar, Likhitta Dugar, and Antariksh Dugar, along with Person Acting in Concert (PAC) Padam Dugar, proposed to acquire up to 6,54,966 fully paid-up equity shares at a price of ₹54 per share. The maximum aggregate consideration for the offer was valued at ₹3,53,68,164, representing 26% of the company’s voting share capital.

Despite the significant size of the mandatory open offer under SEBI (SAST) Regulations, 2011, actual acceptances were minimal. The acquirers accepted the six shares tendered in dematerialized form, resulting in an actual acquisition value of just ₹324.

What the Numbers Show

The divergence between the proposed offer size and actual acceptances highlights a lack of exit interest from existing public shareholders at the offered price. While the acquirers planned to acquire 26% of the voting share capital through the open offer assuming full acceptance, the actual acquisition via this route was negligible. The post-offer shareholding pattern reflects this reality, with the public holding remaining largely unchanged at 34.39% post-offer compared to 49.40% pre-offer, although this figure includes reclassification adjustments.

Shareholding Structure Changes

The acquirers held 3,78,000 shares (15.01%) prior to the public announcement. The open offer was triggered by their agreement to acquire an additional 8,70,500 shares (34.56%) through a Share Purchase Agreement dated June 18, 2026. As of the post-offer advertisement dated September 3, 2026, these transactions had not yet been consummated.

Metric Proposed (Full Acceptance) Actuals
Shares Tendered 6,54,966 6
Offer Price ₹54 ₹54
Aggregate Value ₹3,53,68,164 ₹324
Post-Offer Acquirer Holding 75.57% 49.57%

Upon consummation of the Share Purchase Agreement, the 3,78,000 shares currently classified under the public category will be reclassified to the Promoter/Promoter Group category. This reclassification will further adjust the public holding percentage downwards from the reported 34.39%.

Saffron Capital Advisors Private Limited served as the manager to the open offer, while Bigshare Services Private Limited acted as the registrar. Payment for the accepted shares was made on August 28, 2026.

Historical Stock Returns for Colinz Laboratories

1 Day5 Days1 Month6 Months1 Year5 Years
0.0%-4.15%0.0%0.0%0.0%0.0%

How might the negligible public participation in the open offer impact Colinz Laboratories' future liquidity and trading volume on the stock exchange?

What are the strategic implications for the Dugar family's control over Colinz Laboratories once the pending Share Purchase Agreement is consummated?

Could the low acceptance rate signal underlying concerns among public shareholders regarding the company's valuation or future growth prospects at the ₹54 price point?

More News on Colinz Laboratories

1 Year Returns:0.00%